TLRY - Tilray Brands, Inc.
Canopy Growth is refining its focus on medical and adult-use markets while managing its U.S. expansion strategy through Canopy USA. Tilray Brands has diversified its revenue stream significantly through a large craft beer and beverage portfolio alongside its global cannabis operations.
Tilray's financial results have been weak for years. The company operates in an uncertain industry.
Tilray Brands TodayTLRYTilray Brands$3.44 -0.15 (-4.04%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$3.38▼$20.20Price Target$6.38Add to WatchlistWhen investors hear talk of U.S. cannabis reform, they often look at major Canadian operators.
Tilray Brands, Inc. (TLRY) Q1 2027 Earnings Call Transcript
Tilray Brands NASDAQ: TLRY reported record first-quarter revenue and gross profit, driven by its BrewDog acquisition, international cannabis growth and pharmaceutical distribution operations, while reaffirming fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million.
Tilray Inc (NASDAQ:TLRY), the cannabis and consumer products company, reported record first-quarter revenue of $257.1 million, up 23% from a year earlier, driven by strong growth in beverages and international markets. Gross profit rose 35% to $77.5 million, while gross margin expanded to 30% from 27%, as the company continued to improve profitability across its businesses.
Tilray Brands Inc. (NASDAQ:TLRY) reported a first-quarter 2027 adjusted loss of 2 cents per share on Thursday, beating the consensus loss of 20 cents.
A Q1 FY2027 revenue record from Tilray Brands (NASDAQ:TLRY) is drawing heavy selling, because the segment that built the company's following moved the wrong way. Tilray Brands shares are at $3.
Tilray Brands, Inc. (TLRY) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to break-even earnings per share a year ago.
First-Quarter Results Reinforce Tilray's Progress Converting Global Scale, Disciplined Execution and Category Leadership into Higher Revenue, Expanded Gross Profit and Continued Momentum Record First-Quarter Net Revenue of $257 Million, Up 23% Year-Over-Year, with Gross Margin Expanding by ~300 bps to 30% International Business Accelerates as EMEA Revenue Increases 71%, Growth Led by Medical Cannabis, Beverage and Pharmaceutical Distribution Tilray's Global Beverage Business Delivers $ 101 Million in Revenue, Expands Gross Margin to 41 % and BrewDog Achieves Profitability in Q1 Reduced Outstanding Debt by $42 Million Fiscal Year-to-Date and Ended the Q1 with a Net Cash1 Position, Strengthening Financial Flexibility and the Balance Sheet Tilray Reaffirms Fiscal 2027 Adjusted EBITDA3 Guidance of $68 Million to $75 Million NEW YORK and LONDON and LEAMINGTON, Ontario, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company with leading positions across cannabis, beverage, hospitality and wellness, today reported financial results for its first fiscal quarter ended August 31, 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Tilray Brands (TLRY) has been in a strong downtrend and is now trading near its all-time low. The stock peaked at $4.94 in August and has since pulled back to $3.74.
Hazy Jane Tropical and Krush Test Dummy take Gold as BrewDog builds on its recent sweep at the 2026 World Beer Awards. ELLON, Scotland, Oct. 07, 2026 (GLOBE NEWSWIRE) -- BrewDog , a leader in U.K. craft beer and one of the world's most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), today announced that it has been recognised again for brewing excellence in the prestigious Scottish Beer Awards.
Bold UK-wide campaign puts craft beer back at the centre of culture, celebrating better ingredients, better quality, skilled brewers, beer lovers and the big flavours that make craft worth choosing. BrewDog consumers are back: sales across the brand's top six off-trade retailers are up 2.87 times for Punk IPA vs last year's volume for the same two-week period as the Under New Ownership and Choose Craft campaigns roll out across the UK.
The multi-year cannabis sector bear market is starting to give way to a calculated wave of industry consolidation. Behind the urge to merge is a significant shift in U.S. federal regulatory policy, encouraging better-capitalized operators to secure global supply chains before tax relief drives widespread multiple expansion.
Tilray doesn't have appealing growth prospects, despite diversifying into beverages in recent years. It hit record revenue last year, but it was also deeply in the red.
TherapeuticsMD (NASDAQ: TXMD - Get Free Report) and Tilray Brands (NASDAQ: TLRY - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends. Volatility and Risk TherapeuticsMD has a beta of
Tilray Brands, Inc. (TSE: TLRY - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Thursday. The company traded as low as C$5.18 and last traded at C$5.18, with a volume of 55663 shares trading hands. The stock had previously closed at C$5.34. Tilray Brands Stock Up 1.0% The stock has
Tilray Brands has consistently underperformed the broader equity market in recent years. Recent industry progress may present lucrative opportunities for the company.
10 Barrel Brewing launches Salty Sips Blackberry Refresher, a low-sugar vodka RTD made with real fruit juice, mint and sea salt, now in select PNW markets.
InterCure (NASDAQ: INCR - Get Free Report) and Tilray Brands (NASDAQ: TLRY - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends. Volatility and Risk InterCure has a beta of